Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Injection Site on the Relative Bioavailability of Single Dose of LY3209590 and Evaluation of Absolute Bioavailability of LY3209590 in Healthy Participants

NCT05615532 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT05615532
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05615532 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Injection Site on the Relative Bioavailability of Single Dose of LY3209590 and Evaluation of Absolute Bioavailability of LY3209590 in Healthy Participants
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
November 11, 2022
Completion date
June 28, 2023
Enrollment
168 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy